Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rodon

Showing results (91-100 of 247) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
Cell Reports. Medicine|March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignanciesJuanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.
Genome Medicine|March 30, 2018
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsDavid Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, et al.
Signal Transduction and Targeted Therapy|February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncologyStephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
The Oncologist|August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsAditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Transboundary and Emerging Diseases|October 2, 2020
Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studiesJúlia Vergara-Alert, Jordi Rodon, Jorge Carrillo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2018
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumoursOlivier Mir, Analia Azaro, Jaime Merchan, et al.
Molecular Cancer Therapeutics|June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trialsRodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Cancers|March 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid TumorsFilip Janku, Grace M Choong, Mateusz Opyrchal, et al.
Pageof 25

Showing results (91-100 of 247) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade GliomaBenjamin M Ellingson, Jingwen Yao, Catalina Raymond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.
Cell Reports. Medicine|March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignanciesJuanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.
Genome Medicine|March 30, 2018
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsDavid Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, et al.
Signal Transduction and Targeted Therapy|February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncologyStephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
The Oncologist|August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsAditya Bardia, Mrinal Gounder, Jordi Rodon, et al.
Transboundary and Emerging Diseases|October 2, 2020
Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studiesJúlia Vergara-Alert, Jordi Rodon, Jorge Carrillo, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2018
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumoursOlivier Mir, Analia Azaro, Jaime Merchan, et al.
Molecular Cancer Therapeutics|June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trialsRodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Cancers|March 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid TumorsFilip Janku, Grace M Choong, Mateusz Opyrchal, et al.
Pageof 25